Fig. 5: dTCR-T cells exhibit enhanced anti-leukemia cytotoxicity under NY-ESO-1-specific stimulation. | Oncogene

Fig. 5: dTCR-T cells exhibit enhanced anti-leukemia cytotoxicity under NY-ESO-1-specific stimulation.

From: Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype

Fig. 5

ELISA assays analysis of (A) IFN-γ and (B) TNF-α secretion by the bulk cell culture of NT-T, TCR-T, and dTCR-T cells (from three healthy donors) that were stimulated by 2 × 104 target cells (U937-A2+ with DAC-treated or untreated, and THP-1-A2+ with DAC-treated or untreated) at an effector-to-target (E:T) ratio of 5:1 for 20 h. C, D Increased cytotoxicity of dTCR-T against DAC-treated or untreated AML target cells. A total of 1 × 105 effector cells of the bulk cell culture of NT-T, TCR-T, and dTCR-T were stimulated with DAC-treated or untreated target cells at an E:T ratio of 5:1 for 20 h. E, F Enhanced cytokine secretion of dTCR-T against DAC-treated or untreated 2 × 104 U937-A2+ cells at serial E:T ratios (1:10, 1:20, 1:30, and 1:60) for 20 h. The data are presented as mean ± sd (n = 3). Statistical comparisons between dTCR-T and TCR-T groups were determined by two-tailed unpaired t tests. *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page